---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011610"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-20T23:55:12.604846+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Glucotrack forms Patient Advisory Board to guide implantable CBGM development

## Summary
- Patient Advisory Board (PAB) formed with leading diabetes patient advocates and voices.
- Inaugural PAB meeting held on May 3, 2025; will convene regularly.
- PAB aims to keep patient insights at the forefront of long-term implantable CBGM development.
- CBGM is designed for up to 3 years of continuous blood glucose monitoring, no wearable component.
- CBGM is an Investigational Device limited by federal law to investigational use.

## SEC filing metadata
- accession: 0001641172-25-011610
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000164117225011610/0001641172-25-011610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000164117225011610/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011610
- JSON: https://secwatch.observer/filing/0001641172-25-011610.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011610.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.